Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
NCT03510897 · Quark Pharmaceuticals · PHASE3 · terminated · last registry update 2021-07-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study completed day 90 for primary endpoint but was terminated early for one year follow up due to results not meeting efficacy outcome at Day 90.” | – | Registry record, Quark Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TP53 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-12Results posted on the registry: Aprea Therapeutics, APR-246 + azacitidine + Azacitidine (NCT03745716)
- 2022-06-21Results posted on the registry: Hoffmann-La Roche, Idasanutlin + Cytarabine (NCT03850535)
- 2022-06-21Also stopped (terminated): Hoffmann-La Roche, Idasanutlin + Cytarabine (NCT03850535)
- 2022-03-10Also stopped (withdrawn): M.D. Anderson Cancer Center, Eprenetapopt + Venetoclax (NCT04990778)
- 2022-01-11Also stopped (terminated): Hoffmann-La Roche, Cytarabine + Idasanutlin (NCT02545283)
- 2021-12-13Also stopped (terminated): Peter MacCallum Cancer Centre, Australia, APR-246 (NCT02999893)
- 2021-12-08Also stopped (terminated): Hoffmann-La Roche, Idasanutlin (NCT03287245)
- 2021-12-07Also stopped (terminated): Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT03135262)
- 2021-09-14Results posted on the registry: Hoffmann-La Roche, Cytarabine + Idasanutlin (NCT02545283)
- 2021-08-11Results posted on the registry: Vanderbilt-Ingram Cancer Center, Atezolizumab + Cobimetinib (NCT03566485)
- 2021-08-11Also stopped (terminated): Vanderbilt-Ingram Cancer Center, Atezolizumab + Cobimetinib (NCT03566485)
- 2021-07-27Results posted on the registry: Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT03135262)
- 2021-05-27Results posted on the registry: Hoffmann-La Roche, Idasanutlin (NCT03287245)
- 2021-02-25Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, APR-246 + Azacitidine (NCT03072043)
- 2021-02-21Also stopped (terminated): Eleos, Inc., cenersen + Dexamethasone (NCT02243124)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision